Your trusted source for clear, analytical news.

Company

About Us Contact Us Authors Feedback Grievance

Legal

Terms of Service Privacy Policy Code of Business Cookie Policy Corrections Policy

© 2026AirNews. All Rights Reserved.

Torrent Pharma Shares Drop 2.78% as Net Profit Declines 9.6% YoY | AirNews.in

stocks

Shree Cement Q2 Net Profit Falls 26%, Revenue Surges 18.7%TCS P/E at 13x, Oil Prices Hit $20/Barrel Godrej Properties Q2 Net Profit Slumps 62%, Shares Down 5.5%Pabrai: India Valuations Still Too High, Only 200 Stocks Have Great Governance J&K Bank Q2 Net Profit Climbs 10.6%, Shares Drop 14%Eternal’s Blinkit Q2NOV Ups 79%, Leaving Instamart 33% Behind PL Capital Highlights Power Sector as Buying Opportunity Amid Market Correction Steel Strips Wheels Q2 Net Profit Jumps 228%, Stock Hits ₹467.70 Tonbo Imaging Sees Platform Systems Drive FY29 Revenue, Targets ₹2,500‑3,500 Crore Order Pipeline Edelweiss MF: Midcap Correction Remains Profit Booking, Not Structural Shift Shree Cement Q2 Net Profit Falls 26%, Revenue Surges 18.7%TCS P/E at 13x, Oil Prices Hit $20/Barrel Godrej Properties Q2 Net Profit Slumps 62%, Shares Down 5.5%Pabrai: India Valuations Still Too High, Only 200 Stocks Have Great Governance J&K Bank Q2 Net Profit Climbs 10.6%, Shares Drop 14%Eternal’s Blinkit Q2NOV Ups 79%, Leaving Instamart 33% Behind PL Capital Highlights Power Sector as Buying Opportunity Amid Market Correction Steel Strips Wheels Q2 Net Profit Jumps 228%, Stock Hits ₹467.70 Tonbo Imaging Sees Platform Systems Drive FY29 Revenue, Targets ₹2,500‑3,500 Crore Order Pipeline Edelweiss MF: Midcap Correction Remains Profit Booking, Not Structural Shift

TorrentPharmaPharmaceuticalsQ2ResultsStockPriceEarnings

Torrent Pharma Shares Drop 2.78% as Net Profit Declines 9.6% YoY

about 2 hours ago

Published: October 23, 2026

Torrent Pharma Shares Drop 2.78% as Net Profit Declines 9.6% YoY

Torrent Pharma’s Q2 net profit fell 9.6% YoY to ₹534 crore, missing the ₹544.3 crore estimate, while revenue surged 50.8% to ₹4,979 crore. Shares slid 2.78% to ₹4,482, and the company will report Q3 results on 15 December with no updated guidance.

Shares of Torrent Pharmaceuticals Ltd. slid 2.78% to ₹4,482.00 on the BSE, a drop of ₹128.15 from the previous close.

The company posted Q2 FY27 net profit of ₹534 crore, down 9.6% YoY from ₹591 crore, and below the ₹544.3 crore estimate.

Revenue jumped 50.8% YoY to ₹4,979 crore, beating the ₹4,905.6 crore consensus, while EBITDA rose 54.1% to ₹1,583 crore, missing the ₹1,624.7 crore forecast. The EBITDA margin widened to 32.33% from 31.6%.

Brazil contributed ₹440 crore, up 38% YoY, and US revenue rose ₹417 crore, up 24% YoY. Germany revenue slipped 7% to ₹283 crore.

India sales hit ₹2,181 crore, a 20% rise, outperforming the 12% growth of the domestic pharma market. Supply disruptions and tender losses still weigh on the business.

Torrent will release Q3 FY27 results on 15 December, with no new guidance issued. Analysts remain cautious as the merger integration may continue to dampen short‑term revenue.